
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK). It is useful to distinguish the complex from the unbound peptide: findings about GHK alone, or about related analogues, do not automatically establish the properties of GHK-Cu. The research summarized here includes solution-chemistry experiments and cell-culture studies. These are laboratory findings, not evidence of human or animal benefit.
What copper-binding studies can tell us
The term “copper-binding” covers several questions: which chemical species form under defined conditions, how their relative amounts change, and how stable or spectrally distinct those species are. Those questions can be examined in controlled solutions. They do not, by themselves, establish how a material behaves in a living organism or in a commercial product.
In a 1981 study, Lau and Sarkar examined Cu(II)-GHK chemistry using potentiometric titration and visible-absorption measurements. Their experiments were conducted at 25°C in 0.15 M sodium chloride across pH 3.5–10.6. They reported multiple species in the binary Cu(II)-GHK system and also studied ternary complexes involving histidine. The authors evaluated species distributions, stability constants, and spectra, and proposed structures for some of the complexes.[1]
The same paper reported equilibrium-dialysis measurements under specified conditions. At pH 7.5 and 6°C, with equimolar albumin and GHK, approximately 42% of the copper was bound to the peptide. In a mixture at physiological concentrations, approximately 6% of the copper was associated with low-molecular-weight components.[1] These are results from in-vitro solution experiments. They do not demonstrate transport in a person, tissue delivery, or a clinical effect.

Research comparison
| Study | Research material | Methods and conditions reported | What was measured | Abstract-reported result | Limitation |
|---|---|---|---|---|---|
| Lau & Sarkar, 1981 | Cu(II)-GHK; also ternary systems involving histidine | Potentiometric titration and visible absorption at 25°C in 0.15 M NaCl, pH 3.5–10.6; equilibrium dialysis at pH 7.5 and 6°C | Chemical species, species distributions, stability constants, spectra, and copper association in the stated dialysis mixtures | Multiple species were found in binary Cu(II)-GHK chemistry; ternary histidine complexes were examined. At dialysis, about 42% of copper was peptide-bound in an equimolar albumin:GHK mixture; about 6% was associated with low-MW components in a physiological-concentration mixture. | Defined in-vitro conditions; not clinical transport or efficacy evidence. Structures were proposed for some species, not shown to determine biological function. |
| Maquart et al., 1988 | GHK-Cu in fibroblast cultures | The abstract reports concentrations at which the effect began and was maximal; detailed experimental conditions are not provided there | Collagen synthesis and whether the reported effect accompanied a change in cell number | The abstract says collagen synthesis was stimulated; the effect began between 10⁻¹² and 10⁻¹¹ M, peaked at 10⁻⁹ M, and was independent of a change in cell number. | The abstract does not specify detailed cell species/model, assay, controls, or full methods. Those details are not inferred here. |
| Kang et al., 2009 | Copper-GHK in monolayer keratinocyte cultures and a skin-equivalent model | The abstract reports H&E staining, immunohistochemistry, and Western blotting; detailed dose and sample-size information is not available in the abstract | Keratinocyte proliferation, basal-cell appearance in the model, PCNA and p63 positivity, and integrin α6/β1 expression | The abstract reports increased keratinocyte proliferation; in the skin-equivalent model it reports cuboidal basal cells and increased PCNA, p63, and integrin α6/β1. | Abstract-level evidence only; p63 positivity is not proof of stem-cell function or clinical skin regeneration. |
| Conato et al., 2001 | GHK and two synthetic analogues in copper-complex chemistry and biological-activity tests | Potentiometry, solution calorimetry, UV-Vis, circular dichroism, and EPR; biological activity was also studied in vitro | Chemical behavior of complexes and in-vitro growth-factor activity | The abstract reports differing stoichiometries and stabilities, evidence for binuclear species, and lysine side-chain participation only at alkaline pH. Two analogues showed activity comparable to or higher than GHK. | The analogues are not GHK-Cu and must not be treated as exact product evidence. In-vitro activity does not establish a human effect. |
What the cell-culture reports establish—and leave open
Maquart and colleagues’ 1988 paper specifically reports stimulated collagen synthesis in fibroblast cultures exposed to the GHK-Cu complex. The reported concentration range and the statement that the effect was independent of a change in cell number are the details available in the abstract.[2] The abstract does not supply the cell species or model, assay details, controls, or full methods. Without those details, it would be inappropriate to fill in an experimental design or infer how robustly the finding applies beyond the reported culture study.
Kang and colleagues’ 2009 study tested copper-GHK in monolayer cultured keratinocytes and a skin-equivalent model. The abstract reports increased keratinocyte proliferation and changes in basal-cell appearance, PCNA, p63, and integrin α6/β1. The abstract does not provide the dose or sample size; p63 positivity is not proof of stem-cell function or clinical regeneration.[3]
Conato and colleagues’ 2001 study also examined in-vitro biological activity, but included two synthetic analogues as well as GHK. Its abstract reports that the analogues had growth-factor activity comparable to or higher than GHK; those analogue results cannot be relabeled as GHK-Cu results.[4] None of these abstracts establishes a clinical outcome. These experiments do not support human or veterinary dosing or use.

Reading a product description alongside the research
Product descriptions and seller statements should be treated as statements by the seller rather than independent research validation. SaiyanMed’s GHK-Cu product page is a commercial description; this article does not verify any particular lot or batch. A product name or general research literature does not establish that the composition of a specific batch matches the material used in a cited paper.
For laboratory and procurement review, keep the chemical analysis, cell-culture findings, and batch-specific documentation as separate evidence categories. Record what each report actually measures; leave unanswered attributes unresolved. No batch-matched SaiyanMed GHK-Cu report or product sample was assessed for this article.
References
- Lau, S. J., & Sarkar, B. “The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma.” *Biochemical Journal* 199(3):649–656 (1981). DOI: 10.1042/bj1990649.
- Maquart, F. X., et al. “Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.” *FEBS Letters* 238:343–346 (1988). DOI: 10.1016/0014-5793(88)80509-x.
- Kang, Y. A., et al. “Copper-GHK increases integrin expression and p63 positivity by keratinocytes.” *Archives of Dermatological Research* 301(4):301–306 (2009). DOI: 10.1007/s00403-009-0942-x.
- Conato, C., et al. “Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity.” *Biochimica et Biophysica Acta* 1526(2):199–210 (2001). DOI: 10.1016/S0304-4165(01)00127-1.
Research Use Only Disclaimer
This article is for laboratory research, analytical, and educational purposes only. It is not a validated experimental protocol and is not medical or veterinary advice. The materials discussed are not for administration to humans or animals. Nothing in this article establishes a therapeutic, preventive, diagnostic, or cosmetic use.